Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities

Biochemical Pharmacology

Volumn 85, Issue 5, 2013, Pages 629-643

  Blanco Aparicio, Carmen ^a   Carnero, Amancio ^b,c  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

^c CSIC   (Spain)

Author keywords

Cancer targets; Oncogenes; PIM inhibitors; Pim kinases; Therapeutics

Indexed keywords

1,2,3 TRIAZOLO[4,5 B]PYRIDINE DERIVATIVE; 2 AZAINDOLE DERIVATIVE; A 9538641; ANTINEOPLASTIC AGENT; ARR 0459339; AZD 1208; CX 6258; CXR 1002; DHPCC 9; ETP 39010; ETP 45299; GNE 652; JANUS KINASE; K 00486; M 110; NAPHTHYRIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE PIM 3; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; QUERCETAGETIN; SEL 24 B58; SEL 24B58; SGI 1776; SM 12A; SMI 4A; STAT PROTEIN; TRIAZOLO BENZO[C] 2 6 NAPTHYRIDINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; CELL HOMING; CELL MIGRATION; CRYSTAL STRUCTURE; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; NEOPLASM; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; UPREGULATION; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-PIM-1;

EID: 84873413695     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.09.018     Document Type: Review

References (155)

1. H.T. Cuypers, G. Selten, A. Berns, and A.H. Geurts van Kessel Assignment of the human homologue of Pim-1, a mouse gene implicated in leukemogenesis, to the pter-q12 region of chromosome 6 Hum Genet 72 1986 262 265
2. H.T. Cuypers, G. Selten, W. Quint, M. Zijlstra, E.R. Maandag, and W. Boelens Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region Cell 37 1984 141 150
3. M. Breuer, R. Slebos, S. Verbeek, M. van Lohuizen, E. Wientjens, and A. Berns Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice Nature 340 1989 61 63
4. M. van Lohuizen, S. Verbeek, P. Krimpenfort, J. Domen, C. Saris, and T. Radaszkiewicz Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors Cell 56 1989 673 682
5. K. Blyth, A. Terry, N. Mackay, F. Vaillant, M. Bell, and E.R. Cameron Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging Oncogene 20 2001 295 302
6. G.G. Habets, E.H. Scholtes, D. Zuydgeest, R.A. van der Kammen, J.C. Stam, and A. Berns Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins Cell 77 1994 537 549
7. D. Acton, J. Domen, H. Jacobs, M. Vlaar, S. Korsmeyer, and A. Berns Collaboration of pim-1 and bcl-2 in lymphomagenesis Curr Top Microbiol Immunol 182 1992 293 298
8. T. Schmidt, H. Karsunky, B. Rodel, B. Zevnik, H.P. Elsasser, and T. Moroy Evidence implicating Gfi-1 and Pim-1 in pre-T-cell differentiation steps associated with beta-selection EMBO J 17 1998 5349 5359
9. J. Jonkers, J.J. Weening, M. van der Valk, R. Bobeldijk, and A. Berns Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression Oncogene 18 1999 5982 5990
10. J.D. Allen, E. Verhoeven, J. Domen, M. van der Valk, and A. Berns Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc Oncogene 15 1997 1133 1141
11. M.L. Breuer, H.T. Cuypers, and A. Berns Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas EMBO J 8 1989 743 748
12. H. Mikkers, J. Allen, P. Knipscheer, L. Romeijn, A. Hart, and E. Vink High-throughput retroviral tagging to identify components of specific signaling pathways in cancer Nat Genet 32 2002 153 159
13. J.D. Feldman, L. Vician, M. Crispino, G. Tocco, M. Baudry, and H.R. Herschman Seizure activity induces PIM-1 expression in brain J Neurosci Res 53 1998 502 509
14. U. Konietzko, G. Kauselmann, J. Scafidi, U. Staubli, H. Mikkers, and A. Berns Pim kinase expression is induced by LTP stimulation and required for the consolidation of enduring LTP EMBO J 18 1999 3359 3369
15. M.C. Nawijn, A. Alendar, and A. Berns For better or for worse: the role of Pim oncogenes in tumorigenesis Nat Rev Cancer 11 2011 23 34
16. A.N. Bullock, J. Debreczeni, A.L. Amos, S. Knapp, and B.E. Turk Structure and substrate specificity of the Pim-1 kinase J Biol Chem 280 2005 41675 41682
17. N. Mukaida, Y.Y. Wang, and Y.Y. Li Roles of Pim-3, a novel survival kinase, in tumorigenesis Cancer Sci 102 2011 1437 1442
18. A.N. Bullock, J.E. Debreczeni, O.Y. Fedorov, A. Nelson, B.D. Marsden, and S. Knapp Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase J Med Chem 48 2005 7604 7614
19. O. Kim, T. Jiang, Y. Xie, Z. Guo, H. Chen, and Y. Qiu Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells Oncogene 23 2004 1838 1844
20. M. Narlik-Grassow, C. Blanco-Aparicio, Y. Cecilia, S. Peregrina, B.G. Serelde, and S. Munoz-Galvan Essential role of PIM kinases in sarcoma growth and bone invasion Carcinogenesis 2012 10.1093/carcin/bgs176
21. H. Mikkers, M. Nawijn, J. Allen, C. Brouwers, E. Verhoeven, and J. Jonkers Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors Mol Cell Biol 24 2004 6104 6115
22. Y. Xie, K. Xu, B. Dai, Z. Guo, T. Jiang, and H. Chen The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs Oncogene 25 2006 70 78
23. C.J. Saris, J. Domen, and A. Berns The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG EMBO J 10 1991 655 664
24. L. Brault, C. Gasser, F. Bracher, K. Huber, S. Knapp, and J. Schwaller PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers Haematologica 95 2010 1004 1015
25. M. Lilly, J. Sandholm, J.J. Cooper, P.J. Koskinen, and A. Kraft The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway Oncogene 18 1999 4022 4031
26. R. Amaravadi, and C.B. Thompson The survival kinases Akt and Pim as potential pharmacological targets J Clin Invest 115 2005 2618 2624
27. K. Mizuno, T. Shirogane, A. Shinohara, A. Iwamatsu, M. Hibi, and T. Hirano Regulation of Pim-1 by Hsp90 Biochem Biophys Res Commun 281 2001 663 669
28. K.P. Shay, Z. Wang, P.X. Xing, I.F. McKenzie, and N.S. Magnuson Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway Mol Cancer Res 3 2005 170 181
29. J. Ma, H.K. Arnold, M.B. Lilly, R.C. Sears, and A.S. Kraft Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A Oncogene 26 2007 5145 5153
30. J.A. Losman, X.P. Chen, B.Q. Vuong, S. Fay, and P.B. Rothman Protein phosphatase 2A regulates the stability of Pim protein kinases J Biol Chem 278 2003 4800 4805
31. Z. Wang, N. Bhattacharya, M. Weaver, K. Petersen, M. Meyer, and L. Gapter Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis J Vet Sci 2 2001 167 179
32. E. White The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines Genes Dev 17 2003 1813 1816
33. J. Chen, M. Kobayashi, S. Darmanin, Y. Qiao, C. Gully, and R. Zhao Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation Am J Pathol 175 2009 400 411
34. Y. Zhao, M.S. Hamza, H.S. Leong, C.B. Lim, Y.F. Pan, and E. Cheung Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells Oncogene 27 2008 1 8
35. D.S. Hoover, D.G. Wingett, J. Zhang, R. Reeves, and N.S. Magnuson Pim-1 protein expression is regulated by its 5'-untranslated region and translation initiation factor elF-4E Cell Growth Differ 8 1997 1371 1380
36. B. Culjkovic, I. Topisirovic, L. Skrabanek, M. Ruiz-Gutierrez, and K.L. Borden eIF4E is a central node of an RNA regulon that governs cellular proliferation J Cell Biol 175 2006 415 426
37. X. Huang, L. Ding, K.L. Bennewith, R.T. Tong, S.M. Welford, and K.K. Ang Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation Mol Cell 35 2009 856 867
38. M. Friedmann, M.S. Nissen, D.S. Hoover, R. Reeves, and N.S. Magnuson Characterization of the proto-oncogene pim-1: kinase activity and substrate recognition sequence Arch Biochem Biophys 298 1992 594 601
39. C.K. Palaty, I. Clark-Lewis, D. Leung, and S.L. Pelech Phosphorylation site substrate specificity determinants for the Pim-1 protooncogene-encoded protein kinase Biochem Cell Biol 75 1997 153 162
40. T.L. Aho, J. Sandholm, K.J. Peltola, Y. Ito, and P.J. Koskinen Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity BMC Cell Biol 7 2006 21 29
41. N. Koike, H. Maita, T. Taira, H. Ariga, and S.M. Iguchi-Ariga Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1) FEBS Lett 467 2000 17 21
42. E.M. Rainio, J. Sandholm, and P.J. Koskinen Cutting edge: transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase J Immunol 168 2002 1524 1527
43. L.M. Winn, W. Lei, and S.A. Ness Pim-1 phosphorylates the DNA binding domain of c-Myb Cell Cycle 2 2003 258 262
44. Y. Ishibashi, H. Maita, M. Yano, N. Koike, K. Tamai, and H. Ariga Pim-1 translocates sorting nexin 6/TRAF4-associated factor 2 from cytoplasm to nucleus FEBS Lett 506 2001 33 38
45. Y. Zhang, Z. Wang, and N.S. Magnuson Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells Mol Cancer Res 5 2007 909 922
46. Z. Wang, N. Bhattacharya, P.F. Mixter, W. Wei, J. Sedivy, and N.S. Magnuson Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase Biochim Biophys Acta 1593 2002 45 55
47. D. Morishita, R. Katayama, K. Sekimizu, T. Tsuruo, and N. Fujita Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels Cancer Res 68 2008 5076 5085
48. M. Bachmann, C. Kosan, P.X. Xing, M. Montenarh, I. Hoffmann, and T. Moroy The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C Int J Biochem Cell Biol 38 2006 430 443
49. M. Bachmann, H. Hennemann, P.X. Xing, I. Hoffmann, and T. Moroy The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint J Biol Chem 279 2004 48319 48328
50. B. Yan, M. Zemskova, S. Holder, V. Chin, A. Kraft, and P.J. Koskinen The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death J Biol Chem 278 2003 45358 45367
51. J.J. Gu, Z. Wang, R. Reeves, and N.S. Magnuson PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis Oncogene 28 2009 4261 4271
52. F. Zhang, Z.M. Beharry, T.E. Harris, M.B. Lilly, C.D. Smith, and S. Mahajan PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells Cancer Biol Ther 8 2009 846 853
53. C. Hogan, C. Hutchison, L. Marcar, D. Milne, M. Saville, and J. Goodlad Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma J Biol Chem 283 2008 18012 18023
54. A. Zippo, A. De Robertis, R. Serafini, and S. Oliviero PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation Nat Cell Biol 9 2007 932 944
55. C.J. Fox, P.S. Hammerman, R.M. Cinalli, S.R. Master, L.A. Chodosh, and C.B. Thompson The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor Genes Dev 17 2003 1841 1854
56. Z. Zeng, I.J. Samudio, W. Zhang, Z. Estrov, H. Pelicano, and D. Harris Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP 372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia Cancer Res 66 2006 3737 3746
57. M. Roh, B. Gary, C. Song, N. Said-Al-Naief, A. Tousson, and A. Kraft Overexpression of the oncogenic kinase Pim-1 leads to genomic instability Cancer Res 63 2003 8079 8084
58. T. Moroy, A. Grzeschiczek, S. Petzold, and K.U. Hartmann Expression of a Pim-1 transgene accelerates lymphoproliferation and inhibits apoptosis in lpr/lpr mice Proc Natl Acad Sci USA 90 1993 10734 10738
59. T. Moroy, S. Verbeek, A. Ma, P. Achacoso, A. Berns, and F. Alt E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice Oncogene 6 1991 1941 1948
60. M. Breuer, E. Wientjens, S. Verbeek, R. Slebos, and A. Berns Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras Cancer Res 51 1991 958 963
61. Y. Wu, Y.Y. Wang, Y. Nakamoto, Y.Y. Li, T. Baba, and S. Kaneko Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver Oncogene 29 2010 2228 2237
62. J. Wang, J. Kim, M. Roh, O.E. Franco, S.W. Hayward, and M.L. Wills Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma Oncogene 29 2010 2477 2487
63. W.W. Chen, D.C. Chan, C. Donald, M.B. Lilly, and A.S. Kraft Pim family kinases enhance tumor growth of prostate cancer cells Mol Cancer Res 3 2005 443 451
64. J. Kim, M. Roh, and S.A. Abdulkadir Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity BMC Cancer 10 2010 248 262
65. M. Zemskova, M.B. Lilly, Y.W. Lin, J.H. Song, and A.S. Kraft p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase Mol Cancer Res 8 2010 1126 1141
66. H.G. van der Poel, J. Zevenhoven, and A.M. Bergman Pim1 regulates androgen-dependent survival signaling in prostate cancer cells Urol Int 84 2010 212 220
67. G. Selten, H.T. Cuypers, and A. Berns Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas EMBO J 4 1985 1793 1798
68. G. Wernig, J.R. Gonneville, B.J. Crowley, M.S. Rodrigues, M.M. Reddy, and H.E. Hudon The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes Blood 111 2008 3751 3759
69. M. Nieborowska-Skorska, G. Hoser, P. Kossev, M.A. Wasik, and T. Skorski Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis Blood 99 2002 4531 4539
70. M. Mizuki, S. Ueda, I. Matsumura, J. Ishiko, J. Schwable, and H. Serve Oncogenic receptor tyrosine kinase in leukemia Cell Mol Biol (Noisy-le-grand) 49 2003 907 922
71. K.T. Kim, K. Baird, J.Y. Ahn, P. Meltzer, M. Lilly, and M. Levis Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival Blood 105 2005 1759 1767
72. M. Adam, V. Pogacic, M. Bendit, R. Chappuis, M.C. Nawijn, and J. Duyster Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL Cancer Res 66 2006 3828 3835
73. S. Agrawal, S. Koschmieder, N. Baumer, N.G. Reddy, W.E. Berdel, and C. Muller-Tidow Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation Leukemia 22 2008 78 86
74. W. Chen, A.R. Kumar, W.A. Hudson, Q. Li, B. Wu, and R.A. Staggs Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells Cancer Cell 13 2008 432 440
75. Y.L. Hu, E. Passegue, S. Fong, C. Largman, and H.J. Lawrence Evidence that the Pim1 kinase gene is a direct target of HOXA9 Blood 109 2007 4732 4738
76. M. Mizuki, J. Schwable, C. Steur, C. Choudhary, S. Agrawal, and B. Sargin Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations Blood 101 2003 3164 3173
77. B.G. Bajaj, S.C. Verma, K. Lan, M.A. Cotter, Z.L. Woodman, and E.S.K.S.H.V. Robertson encoded LANA upregulates Pim-1 and is a substrate for its kinase activity Virology 351 2006 18 28
78. E.M. Rainio, H. Ahlfors, K.L. Carter, M. Ruuska, S. Matikainen, and E. Kieff Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity Virology 333 2005 201 206
79. D. Rossi, E. Berra, M. Cerri, C. Deambrogi, C. Barbieri, and S. Franceschetti Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma Haematologica 91 2006 1405 1409
80. L. Pasqualucci, P. Neumeister, T. Goossens, G. Nanjangud, R.S. Chaganti, and R. Kuppers Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas Nature 412 2001 341 346
81. N. Shah, B. Pang, K.G. Yeoh, S. Thorn, C.S. Chen, and M.B. Lilly Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal Eur J Cancer 44 2008 2144 2151
82. M. Bachmann, and T. Moroy The serine/threonine kinase Pim-1 Int J Biochem Cell Biol 37 2005 726 730
83. S. Guo, X. Mao, J. Chen, B. Huang, C. Jin, and Z. Xu Overexpression of Pim-1 in bladder cancer J Exp Clin Cancer Res 29 2010 161 167
84. M.E. Nga, N.N. Swe, K.T. Chen, L. Shen, M.B. Lilly, and S.P. Chan PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications Int J Exp Pathol 91 2010 34 43
85. S.M. Dhanasekaran, T.R. Barrette, D. Ghosh, R. Shah, S. Varambally, and K. Kurachi Delineation of prognostic biomarkers in prostate cancer Nature 412 2001 822 826
86. S.M. Mumenthaler, P.Y. Ng, A. Hodge, D. Bearss, G. Berk, and S. Kanekal Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes Mol Cancer Ther 8 2009 2882 2893
87. J. Chen, M. Kobayashi, S. Darmanin, Y. Qiao, C. Gully, and R. Zhao Pim-1 plays a pivotal role in hypoxia-induced chemoresistance Oncogene 28 2009 2581 2592
88. C. Reiser-Erkan, M. Erkan, Z. Pan, S. Bekasi, N.A. Giese, and S. Streit Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma Cancer Biol Ther 7 2008 1352 1359
89. J. Tamburini, A.S. Green, V. Bardet, N. Chapuis, S. Park, and L. Willems Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia Blood 114 2009 1618 1627
90. A. Huttmann, L. Klein-Hitpass, J. Thomale, R. Deenen, A. Carpinteiro, and H. Nuckel Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status Leukemia 20 2006 1774 1782
91. A.M. Cohen, B. Grinblat, H. Bessler, D. Kristt, A. Kremer, and A. Schwartz Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma Leuk Lymphoma 45 2004 951 955
92. P.S. Hammerman, C.J. Fox, M.J. Birnbaum, and C.B. Thompson Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival Blood 105 2005 4477 4483
93. H. Dai, R. Li, T. Wheeler, A. Diaz de Vivar, A. Frolov, and S. Tahir Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer Prostate 65 2005 276 286
94. Y.Y. Li, B.K. Popivanova, Y. Nagai, H. Ishikura, C. Fujii, and N. Mukaida Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines Cancer Res 66 2006 6741 6747
95. C. Fujii, Y. Nakamoto, P. Lu, K. Tsuneyama, B.K. Popivanova, and S. Kaneko Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines Int J Cancer 114 2005 209 218
96. B.K. Popivanova, Y.Y. Li, H. Zheng, K. Omura, C. Fujii, and K. Tsuneyama Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis Cancer Sci 98 2007 321 328
97. H.C. Zheng, K. Tsuneyama, H. Takahashi, S. Miwa, T. Sugiyama, and B.K. Popivanova Aberrant Pim-3 expression is involved in gastric adenoma- adenocarcinoma sequence and cancer progression J Cancer Res Clin Oncol 134 2008 481 488
98. B. Deneen, S.M. Welford, T. Ho, F. Hernandez, I. Kurland, and C.T. Denny PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins Mol Cell Biol 23 2003 3897 3908
99. X.Y. Yang, C.P. Ren, L. Wang, H. Li, C.J. Jiang, and H.B. Zhang Identification of differentially expressed genes in metastatic and non-metastatic nasopharyngeal carcinoma cells by suppression subtractive hybridization Cell Oncol 27 2005 215 223
100. N.M. Santio, R.L. Vahakoski, E.M. Rainio, J.A. Sandholm, S.S. Virtanen, and M. Prudhomme Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion Mol Cancer 9 2010 279 291
101. P. Zhang, H. Wang, X. Min, Y. Wang, J. Tang, and J. Cheng Pim-3 is expressed in endothelial cells and promotes vascular tube formation J Cell Physiol 220 2009 82 90
102. M. Mancini, and A. Toker NFAT proteins: emerging roles in cancer progression Nat Rev Cancer 9 2009 810 820
103. R. Swords, K. Kelly, J. Carew, S. Nawrocki, D. Mahalingam, and J. Sarantopoulos The Pim kinases: new targets for drug development Curr Drug Targets 12 2011 2059 2066
104. T. Morwick Pim kinase inhibitors: a survey of the patent literature Expert Opin Ther Pat 20 2010 193 212
105. K.C. Qian, J. Studts, L. Wang, K. Barringer, A. Kronkaitis, and C. Peng Expression, purification, crystallization and preliminary crystallographic analysis of human Pim-1 kinase Acta Crystallogr Sect F Struct Biol Cryst Commun 61 2005 96 99
106. V. Pogacic, A.N. Bullock, O. Fedorov, P. Filippakopoulos, C. Gasser, and A. Biondi Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity Cancer Res 67 2007 6916 6924
107. C. Blanco-Aparicio, A.M. Collazo, J. Oyarzabal, J.F. Leal, M.I. Albaran, and F.R. Lima Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition Cancer Lett 300 2011 145 153
108. A.N. Bullock, S. Russo, A. Amos, N. Pagano, H. Bregman, and J.E. Debreczeni Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor PLoS One 4 2009 e7112
109. A. Kumar, V. Mandiyan, Y. Suzuki, C. Zhang, J. Rice, and J. Tsai Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma J Mol Biol 348 2005 183 193
110. M.D. Jacobs, J. Black, O. Futer, L. Swenson, B. Hare, and M. Fleming Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002 J Biol Chem 280 2005 13728 13734
111. K.C. Qian, L. Wang, E.R. Hickey, J. Studts, K. Barringer, and C. Peng Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase J Biol Chem 280 2005 6130 6137
112. M. Isaac, A. Siu, and J. Jongstra The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms Drug Resist Updat 14 2011 203 211
113. I.W. Cheney, S. Yan, T. Appleby, H. Walker, T. Vo, and N. Yao Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase Bioorg Med Chem Lett 17 2007 1679 1683
114. Y. Tong, K.D. Stewart, S. Thomas, M. Przytulinska, E.F. Johnson, and V. Klinghofer Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling Bioorg Med Chem Lett 18 2008 5206 5208
115. R. Grey, A.C. Pierce, G.W. Bemis, M.D. Jacobs, C.S. Moody, and R. Jajoo Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase Bioorg Med Chem Lett 19 2009 3019 3022
116. K. Qian, L. Wang, C.L. Cywin, B.T. Farmer 2nd, E. Hickey, and C. Homon Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode J Med Chem 52 2009 1814 1827
117. M. Lopez-Ramos, R. Prudent, V. Moucadel, C.F. Sautel, C. Barette, and L. Lafanechere New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights FASEB J 24 2010 3171 3185
118. G.A. Nishiguchi, G. Atallah, C. Bellamacina, M.T. Burger, Y. Ding, and P.H. Feucht Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases Bioorg Med Chem Lett 21 2011 6366 6369
119. K. Tsuganezawa, H. Watanabe, L. Parker, H. Yuki, S. Taruya, and Y. Nakagawa A novel Pim-1 kinase inhibitor targeting residues that bind the substrate peptide J Mol Biol 417 2012 240 252
120. Y. Xiang, B. Hirth, G. Asmussen, H.P. Biemann, K.A. Bishop, and A. Good The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors Bioorg Med Chem Lett 21 2011 3050 3056
121. M.A. Hospital, A.S. Green, C. Lacombe, P. Mayeux, D. Bouscary, and J. Tamburini The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells Blood 119 2012 1791 1792
122. Y. Xie, M. Burcu, D.E. Linn, Y. Qiu, and M.R. Baer Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression Mol Pharmacol 78 2010 310 318
123. L.S. Chen, S. Redkar, D. Bearss, W.G. Wierda, and V. Gandhi Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells Blood 114 2009 4150 4157
124. L.S. Chen, S. Redkar, P. Taverna, J.E. Cortes, and V. Gandhi Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia Blood 118 2011 693 702
125. K.R. Kelly, C.M. Espitia, P. Taverna, G. Choy, S. Padmanabhan, and S.T. Nawrocki Targeting PIM kinase activity significantly augments the efficacy of cytarabine Br J Haematol 156 2011 129 132
126. D. Mahalingam, C.M. Espitia, E.C. Medina, J.A. Esquivel 2nd, K.R. Kelly, and D. Bearss Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma Br J Cancer 105 2011 1563 1573
127. K.P. Keeton, M. Alimzhanov, M. Grondine, Y. Chen, J. Brown, and K. McEachern AZD1208, a novel, potent and selective Pan PIM kinase inhibitor, demonstrates efficacy in models of acute myeloid leukemia 53rd ASH Annual Meeting 2011 Abstract nr 1540
128. L.A. Dakin, M.H. Block, H. Chen, E. Code, J.E. Dowling, and X. Feng Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases Bioorg Med Chem Lett 22 2012 4599 4604
129. Z. Xia, C. Knaak, J. Ma, Z.M. Beharry, C. McInnes, and W. Wang Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases J Med Chem 52 2009 74 86
130. Z. Beharry, M. Zemskova, S. Mahajan, F. Zhang, J. Ma, and Z. Xia Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells Mol Cancer Ther 8 2009 1473 1483
131. Y.W. Lin, Z.M. Beharry, E.G. Hill, J.H. Song, W. Wang, and Z. Xia A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma Blood 115 2010 824 833
132. Z. Beharry, S. Mahajan, M. Zemskova, Y.W. Lin, B.G. Tholanikunnel, and Z. Xia The Pim protein kinases regulate energy metabolism and cell growth Proc Natl Acad Sci USA 108 2011 528 533
133. J.H. Song, and A.S. Kraft Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737 Cancer Res 72 2012 294 303
134. R. Akue-Gedu, E. Rossignol, S. Azzaro, S. Knapp, P. Filippakopoulos, and A.N. Bullock Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors J Med Chem 52 2009 6369 6381
135. K.W. Brzózka, M. Guratowska, K. Krawczyńska, A. Kłosowska-Wardȩga, M. Zurawska, and E. Trȩbacz Preclinical development of a Pim kinase inhibitor for cancer treatment Proceedings of the 103rd annual meeting of the American Association for Cancer Research AACR, Chicago, IL/Philadelphia, PA, March 31-April 4 2012 Cancer Res 2012;72(8 Suppl.):Abstract nr 2826 2012.
136. M. Chang, N. Kanwar, E. Feng, A. Siu, X. Liu, and D. Ma PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation Mol Cancer Ther 9 2010 2478 2487
137. A. Siu, C. Virtanen, and J. Jongstra PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells Oncotarget 2 2011 1134 1144
138. A.J.B. Ebens, Y.-H. Chen, G. Deshmukh, J. Drummond, C. Du, and M. Eby A selective PIM kinase inhibitor is highly active in multiple myeloma: the biology of single agent and PI3K/AKT/mTOR combination activity 53rd ASH annual meeting 2011 2011 Abstract nr. 3001
139. V.B. Munugalavadla, Y.-H. Chen, G. Deshmukh, J. Drummond, C. Du, and M. Eby A selective PIM kinase inhibitor is highly active in multiple myeloma: mechanism of action and signal transduction studies 53rd ASH annual meeting 2011 Abstract nr 4084
140. A.T. Fathi, O. Arowojolu, I. Swinnen, T. Sato, T. Rajkhowa, and D. Small A potential therapeutic target for FLT3-ITD AML: PIM1 kinase Leuk Res 36 2012 224 231
141. Z.F. Tao, L.A. Hasvold, J.D. Leverson, E.K. Han, R. Guan, and E.F. Johnson Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases J Med Chem 52 2009 6621 6636
142. R. Grundler, L. Brault, C. Gasser, A.N. Bullock, T. Dechow, and S. Woetzel Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration J Exp Med 206 2009 1957 1970
143. F. Pierre, P.C. Chua, S.E. O'Brien, A. Siddiqui-Jain, P. Bourbon, and M. Haddach Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer Mol Cell Biochem 356 2011 37 43
144. F. Pierre, E. Stefan, A.S. Nedellec, M.C. Chevrel, C.F. Regan, and A. Siddiqui-Jain 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity Bioorg Med Chem Lett 21 2011 6687 6692
145. M.M.J. Haddach, M.K. Schwaebe, F. Pierre, S.E. O'Brien, C.T.J. Borsan, and N. Raffaele Discovery of CX-6258. A potent, selective, and orally efficacious pan-Pim kinases inhibitor ACS Med Chem Lett 3 2012 135 139
146. M.B. Wozniak, R. Villuendas, J.R. Bischoff, C.B. Aparicio, J.F. Martinez Leal, and P. de La Cueva Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma Haematologica 95 2010 613 621
147. E. Martin-Sanchez, M. Sanchez-Beato, M.E. Rodriguez, B. Sanchez-Espiridion, C. Gomez-Abad, and J.R. Bischoff HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines Br J Haematol 152 2011 352 356
148. C. Gomez-Abad, H. Pisonero, C. Blanco-Aparicio, G. Roncador, A. Gonzalez-Menchen, and J.A. Martinez-Climent PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma Blood 118 2011 5517 5527
149. J. Pastor, J. Oyarzabal, G. Saluste, R.M. Alvarez, V. Rivero, and F. Ramos Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors Bioorg Med Chem Lett 22 2012 1591 1597
150. S. Holder, M. Zemskova, C. Zhang, M. Tabrizizad, R. Bremer, and J.W. Neidigh Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase Mol Cancer Ther 6 2007 163 172
151. M. Willert, A. Augstein, D.M. Poitz, A. Schmeisser, R.H. Strasser, and R.C. Braun-Dullaeus Transcriptional regulation of Pim-1 kinase in vascular smooth muscle cells and its role for proliferation Basic Res Cardiol 105 2010 267 277
152. H. Nakano, N. Saito, L. Parker, Y. Tada, M. Abe, and K. Tsuganezawa Rational evolution of a novel type of potent and selective proviral integration site in moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound J Med Chem 55 2012 5151 5164
153. A.D. Barnett, S. Murray, C. Chamberlain, M. Plummer, S. Evans, and T.R.J. MacPherson Antitumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: human tumor xenograft efficacy and in vitro mode of action EJC Suppl 8 2010 45 46
154. V. Batra, J.M. Maris, M.H. Kang, C.P. Reynolds, P.J. Houghton, and D. Alexander Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program Pediatr Blood Cancer 2011 10.1002/pbc.23364
155. D. Drygin, C.B. Ho, M. Omori, J. Bliesath, C. Proffitt, and R. Rice Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer Biochem Biophys Res Commun 415 2011 163 167